EN DE
Watch BioRestorative Therapies, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioRestorative Therapies, Inc (BRTX) fair value: what the stock is really worth

As of Oct 21, 2026: fair value (intrinsic value) of BioRestorative Therapies, Inc stock $3.51, price $1.53, upside +129.4%, quality 35 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

BT BioRestorative Therapies, Inc logo Thin data Oct 21, 2026

BioRestorative Therapies, Inc

BRTX · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

The stock costs 56% less than our calculation considers fair.

Fair value $3.51 · Strongly undervalued (+129.4%)
Mixed Growth (revenue 5y +36.1 %/yr in USD)
Moderate debt
Mixed vs. peers (3/7)
Quality 35/100
Negative free cash flow
Narrow moat 23/100 · thin data
Thin data
Watch BioRestorative Therapies, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.60 $0.1437 Fair Value $3.51 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 21, 2026.

How to read this chart

60‑month range $0.1437 – $21.60 · fair‑value band $1.74 – $5.39 · the $1.53 price screens below the $3.51 fair value. Dashed = 300-day average. As of Oct 21, 2026.

Follow BioRestorative Therapies in your weekly email

Every Wednesday you see whether BioRestorative Therapies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders.

Show moreShow less

Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.

The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body.

The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Stock analysis

BioRestorative Therapies, Inc (BRTX) currently trades at $1.53, while our model-based Fair Value estimate is $3.51, implying the stock looks roughly 56.4% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.74 (bear) to $5.39 (bull), the price of $1.53 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BioRestorative Therapies, Inc reported revenue of $360K in FY2025 versus $46.0K in FY2021, a compound +67.2%/yr. Reported net income was −$14.2M in FY2025.

Key figures

Market cap $2.2M Micro · P/S ratio 6.02 · EPS (TTM) $−21.49 · Dividend yield 12.6% · Return on equity −241% · Return on assets (EBIT) −166% · Operating margin −14,613% · Revenue (TTM) $358K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and 965% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 129%, BRTX screens cheaper than that median.

Fair Value models

Bear $1.74 Fair Value $3.51 Bull $5.39
Price $1.53 · Upside +129.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
DDM Multi-Stage $1.74 $3.02 $3.70 65
Gordon GGM $1.74 $3.51 $5.39 64
All 2 models by family
Dividend Discount
Gordon GGM $1.74 $3.51 $5.39 64
DDM Multi-Stage $1.74 $3.02 $3.70 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Momentum 91
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 40
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−10.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.1%
Start year 2020 (pandemic). Over 10 years: −5.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,574.1% (2020) → −4,350.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BRTX, get fair value alerts →

Compare BioRestorative Therapies, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 596 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside +125.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −7.3% · Below median
Dividend yield (12 months) 12.6% · Top 25%
Balance sheet
Debt / equity 0.54× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.04× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 6.02× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)73 · sector 97
DIVIDEND (yield)100 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $805.67 $1,275 +58% vs BRTX
Vertex Pharmaceuticals Incorporated VRTX $514.65 $566.12 +10% vs BRTX
Samsung Biologics Co 207940 1,417,000 KRW 1,558,700 KRW +10% vs BRTX
WuXi Biologics (Cayman) Inc 2269 HK$49.40 HK$54.34 +10% vs BRTX
argenx SE ARGX $890.05 $908.40 +2% vs BRTX
Alnylam Pharmaceuticals, Inc ALNY $225.10 $217.88 −3% vs BRTX
CSL Limited CSL A$196.08 A$178.71 −9% vs BRTX
BeOne Medicines AG ONC $386.46 $254.12 −34% vs BRTX
Celltrion, Inc 068270 197,600 KRW 74,944 KRW −62% vs BRTX
Royalty Pharma plc RPRX $62.15 $19.01 −69% vs BRTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioRestorative Therapies, Inc · Fair Value
$3.51 +56%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BioRestorative Therapies, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BRTX

Frequently asked questions

Is BioRestorative Therapies, Inc (BRTX) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of $3.51 versus a price of $1.53, about +129% upside (undervalued).
What is the fair value of BRTX?
Our model-based fair value for BioRestorative Therapies, Inc is $3.51 (as of Oct 21, 2026), built from audited fundamentals. The current price: $1.53.
What is the quality score of BRTX?
BioRestorative Therapies, Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioRestorative Therapies, Inc (BRTX)?
Our model-based price target is the fair value of $3.51 (as of Oct 21, 2026) from 2 valuation models. Cautious scenario $1.74, optimistic scenario $5.39. It is a calculation from audited fundamentals, not an analyst target.
What is the BioRestorative Therapies, Inc stock forecast for 2026?
Our models put fair value at $3.51, about +129% upside versus a price of $1.53 (undervalued). Cautious scenario $1.74, optimistic scenario $5.39. The calculation is refreshed regularly with new filings.
What is the revenue of BioRestorative Therapies, Inc (BRTX)?
BioRestorative Therapies, Inc reported trailing-twelve-month revenue of about $358K (latest available figure, as of Oct 21, 2026).
Does BioRestorative Therapies, Inc pay a dividend?
BioRestorative Therapies, Inc currently shows a dividend yield of 12.56% relative to its recent price (as of Oct 21, 2026).
What is the intrinsic value of BioRestorative Therapies, Inc (BRTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioRestorative Therapies, Inc it is $3.51 per share (as of Oct 21, 2026), against a price of $1.53. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is BioRestorative Therapies, Inc stock overvalued or undervalued in 2026?
As of Oct 21, 2026, BRTX trades below its calculated fair value: price $1.53, fair value $3.51, a gap of about +129% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRTX?
No. The price is what the market pays today ($1.53); the fair value is what the company's own numbers justify ($3.51). For BioRestorative Therapies, Inc the two are $1.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioRestorative Therapies, Inc worth?
The market values BioRestorative Therapies, Inc at about $2.2M (market capitalisation, as of Oct 21, 2026). Per share that is $1.53; our models calculate a fair value of $3.51 per share.
What do the bullish and bearish scenarios say about BRTX?
Our models span a range for BioRestorative Therapies, Inc: cautious scenario $1.74, base $3.51, optimistic $5.39 per share (as of Oct 21, 2026, price $1.53). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioRestorative Therapies, Inc (BRTX)?
Balance-sheet figures for BioRestorative Therapies, Inc (as of Oct 21, 2026): return on equity −241.1%, debt of 0.54 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is BRTX from its 52-week high?
BioRestorative Therapies, Inc trades at $1.53, about 45% below its 52-week high of $2.76 and 965% above the low of $0.1437 (as of Oct 21, 2026). Distance from the high says nothing about value: that is what the fair value of $3.51 is for.
Which stocks are comparable to BioRestorative Therapies, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioRestorative Therapies, Inc stock attractive at the current price?
The data as of Oct 21, 2026: price $1.53, calculated fair value $3.51 (+129%), Quality Score 35/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRTX calculated?
We run BioRestorative Therapies, Inc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.51, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6 % above its aggregate fair value. BioRestorative Therapies, Inc currently trades 56 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioRestorative Therapies, Inc (BRTX)?
The closing price on Oct 21, 2026 was $1.53. Our model-based fair value is $3.51, about +129% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioRestorative Therapies, Inc right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($1.74). The market is more pessimistic than our downside scenario. The model range is unusually wide ($1.74 to $5.39). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of BioRestorative Therapies, Inc

How large is the market capitalisation of BioRestorative Therapies, Inc (BRTX)?
The market capitalisation of BioRestorative Therapies, Inc is $2.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioRestorative Therapies, Inc (BRTX)?
The price-to-sales ratio of BioRestorative Therapies, Inc is 6.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioRestorative Therapies, Inc (BRTX)?
Earnings per share at BioRestorative Therapies, Inc are $−21.49. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BioRestorative Therapies, Inc (BRTX)?
The dividend yield of BioRestorative Therapies, Inc is 12.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of BioRestorative Therapies, Inc (BRTX)?
The return on equity (ROE) of BioRestorative Therapies, Inc is −241% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioRestorative Therapies, Inc (BRTX)?
On an EBIT basis the return on assets of BioRestorative Therapies, Inc is −166% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioRestorative Therapies, Inc (BRTX)?
The operating margin of BioRestorative Therapies, Inc is −14,613% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioRestorative Therapies, Inc (BRTX)?
Revenue at BioRestorative Therapies, Inc is growing −7.3% versus a year earlier (3y avg +44.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioRestorative Therapies, Inc (BRTX) generate?
The free cash flow of BioRestorative Therapies, Inc is −$10.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BioRestorative Therapies, Inc (BRTX) hold?
BioRestorative Therapies, Inc holds more cash than debt, $1.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BioRestorative Therapies, Inc in the live analysis

One click puts BioRestorative Therapies, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.